JP2022522405A5 - - Google Patents
Info
- Publication number
- JP2022522405A5 JP2022522405A5 JP2021543386A JP2021543386A JP2022522405A5 JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5 JP 2021543386 A JP2021543386 A JP 2021543386A JP 2021543386 A JP2021543386 A JP 2021543386A JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- mhc class
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814721P | 2019-03-06 | 2019-03-06 | |
| US62/814,721 | 2019-03-06 | ||
| PCT/US2020/021138 WO2020181062A1 (en) | 2019-03-06 | 2020-03-05 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022522405A JP2022522405A (ja) | 2022-04-19 |
| JP2022522405A5 true JP2022522405A5 (enExample) | 2023-03-09 |
Family
ID=72338760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543386A Pending JP2022522405A (ja) | 2019-03-06 | 2020-03-05 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220105162A1 (enExample) |
| EP (1) | EP3935080A4 (enExample) |
| JP (1) | JP2022522405A (enExample) |
| WO (1) | WO2020181062A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| LT3615674T (lt) | 2017-04-28 | 2024-09-25 | The Regents Of The University Of Colorado, A Body Corporate | Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2024504194A (ja) * | 2021-01-29 | 2024-01-30 | エランコ アニマル ヘルス ゲー・エム・ベー・ハー | 自己寛容を破壊するためのワクチン組成物 |
| WO2022226073A1 (en) * | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides and methods of use thereof |
| AU2022261908A1 (en) * | 2021-04-21 | 2023-10-05 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CA3216273A1 (en) * | 2021-04-21 | 2022-10-27 | Ronald D. SEIDEL III | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| KR20240023035A (ko) | 2021-05-10 | 2024-02-20 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | 자가면역 치료를 위한 hla 조작 방법 및 조성물 |
| CN117715929A (zh) * | 2021-07-29 | 2024-03-15 | 南特细胞公司 | 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体 |
| WO2025111562A1 (en) * | 2023-11-22 | 2025-05-30 | Cue Biopharma, Inc. | Mhc class ii protein complexes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| WO1996004314A1 (en) * | 1994-07-29 | 1996-02-15 | Dade International, Inc. | Mhc complexes and uses thereof |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| EP1578917A4 (en) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007223855B2 (en) | 2006-03-06 | 2013-05-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| US9695410B2 (en) * | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
| WO2015195531A2 (en) * | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| EP3291832B1 (en) * | 2015-05-06 | 2025-09-03 | UTI Limited Partnership | Nanoparticle compositions for sustained therapy |
| CN109689096A (zh) * | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| US20180127481A1 (en) * | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
-
2020
- 2020-03-05 JP JP2021543386A patent/JP2022522405A/ja active Pending
- 2020-03-05 EP EP20765925.1A patent/EP3935080A4/en not_active Withdrawn
- 2020-03-05 WO PCT/US2020/021138 patent/WO2020181062A1/en not_active Ceased
-
2021
- 2021-08-05 US US17/394,972 patent/US20220105162A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,201 patent/US20250242005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022522405A5 (enExample) | ||
| JP2022522404A5 (enExample) | ||
| JP2021500855A5 (enExample) | ||
| Todd et al. | A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus | |
| Choo | The HLA system: genetics, immunology, clinical testing, and clinical implications | |
| Steinman | The T lymphocyte in experimental allergic encephalomyelitis | |
| Todd et al. | A molecular basis for MHC class II—associated autoimmunity | |
| Kelly et al. | A new human HLA class II-related locus, DM | |
| Spies et al. | Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer | |
| Flajnik et al. | Evolution of the major histocompatibility complex: molecular cloning of major histocompatibility complex class I from the amphibian Xenopus. | |
| Czaja | Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis | |
| JP2022536581A5 (enExample) | ||
| JP2022534846A5 (enExample) | ||
| JP2022515330A5 (enExample) | ||
| JP2019512222A5 (enExample) | ||
| Gregersen | HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease | |
| JP2023541366A5 (enExample) | ||
| Parham et al. | HLA-A, B, C: patterns of polymorphism in peptide-binding proteins | |
| Cook et al. | Structural Studies on the Murine Ia Alloantigens: IV. NH2-Terminal Sequence Analysis of Allelic Products of the IA and IE/C Subregions | |
| EP0286447B1 (en) | Method and agents relating to prophylactic treatment of autoimmune diseases | |
| Hurley et al. | Polymorphism of the HLA-DR1 haplotype in American blacks. Identification of a DR1 beta-chain determinant recognized in the mixed lymphocyte reaction. | |
| Ababou et al. | Evidence for the expression of three different BoLA-class II molecules on the bovine BL-3 cell line: determination of a non-DR non-DQ gene product | |
| Nepom | MHC genes in HLA-associated disease | |
| Weyand et al. | Mapping of allospecific T-cell recognition sites encoded by the HLA-DR4 β1-chain | |
| Deschamps et al. | The role of genetic predisposition to type I (insulin-dependent) diabetes mellitus |